Topiramate-13C

Topiramate-13C (McN 4853-13C) is 13C labeled Topiramate. Topiramate (McN 4853) is a broad-spectrum antiepileptic agent. Topiramate is a GluR5 receptor antagonist. Topiramate produces its antiepileptic effects through enhancement of GABAergic activity, inhibition of kainate/AMPA receptors, inhibition of voltage-sensitive sodium and calcium channels, increases in potassium conductance, and inhibition of carbonic anhydrase[1][2][3].

Product Specifications

Product Name Alternative

McN 4853-13C; RWJ 17021-13C

UNSPSC

12352005

Target

Calcium Channel; Carbonic Anhydrase; GABA Receptor; iGluR; Isotope-Labeled Compounds; Potassium Channel; Sodium Channel

Related Pathways

Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; Neuronal Signaling; Others

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Smiles

NS(O[13CH2][C@]12[C@](OC(C)(O2)C)([H])[C@@]3([H])[C@@](OC(C)(O3)C)([H])CO1)(=O)=O

Molecular Formula

C11 13CH21NO8S

Molecular Weight

340.35

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Kaminski RM, et al. Topiramate selectively protects against seizures induced by ATPA, a GluR5 kainate receptor agonist. Neuropharmacology. 2004 Jun;46 (8) :1097-104.|[3]Lyseng-Williamson KA, et al. Topiramate: a review of its use in the treatment of epilepsy. Drugs. 2007;67 (15) :2231-56.|[4]Nakamura J, et al. Target pharmacology of topiramate, a new antiepileptic drug. Nihon Yakurigaku Zasshi. 2000 Jan;115 (1) :53-7.